An FDA record shows the agency had previously granted accelerated approval to encorafenib paired with cetuximab and mFOLFOX6 before later converting to traditional approval for BRAF V600E-mutant metastatic colorectal.
FDA (4)
The agency's 2023 clearance applies to patients with locally advanced or metastatic urothelial carcinoma who cannot receive cisplatin-based chemotherapy.
FDA (10)
Regulatory decisionUpdated
Breyanzi gained accelerated approval for follicular lymphoma on May 15, 2024, two weeks before a full approval for mantle cell lymphoma.
FDA (2)
Editas said it received ethics and regulatory clearance to begin its Phase 1/2 Strive study of EDIT-401 in Australia, with dosing expected by year-end and initial safety data due in early 2027.
SEC filing